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Résumé en
anglais
The prognostic implications of DNMT3A genotype in T-ALL are incompletely
understood. We performed comprehensive genetic and clinicobiological analyses of T-
ALL patients with DNMT3A mutations treated during the GRAALL-2003 and -2005
studies. Eighteen of 198 cases (9.1%) had DNMT3A alterations. Two patients also had
DNMT3A mutations in non-leukemic cell DNA, providing the first potential evidence of
age-related clonal hematopoiesis in T-ALL. DNMT3A mutation was associated with
older age (median 43.9 years v 29.4 years, p < 0.001), immature T-receptor genotype
(53.3% v 24.4%, p = 0.016) and lower remission rates (72.2% mutated v 94.4% non-
mutated, p = 0.006). DNMT3A alterations were significantly associated with worse
clinical outcome, with higher cumulative incidence of relapse (CIR, HR 2.33, 95% CI
1.05-5.16, p = 0.037) and markedly poorer event-free survival (EFS, HR 3.22, 95% CI
1.81-5.72, p < 0.001) and overall survival (OS, HR 2.91, 95% CI 1.56-5.43, p = 0.001).
Adjusting for age as a covariate, or restricting the analysis to patients over 40 years,
who account for almost 90% of DNMT3A-mutated cases, did not modify these
observations. In multivariate analysis using the risk factors that were used to stratify
treatment during the GRAALL studies, DNMT3A mutation was significantly associated
with shorter EFS (HR 2.33, 95% CI 1.06 - 4.04, p = 0.02). Altogether, these results
identify DNMT3A genotype as a predictor of aggressive T-ALL biology. The
GRAALL-2003 and -2005 studies were registered at http://www.clinicaltrials.gov [26]
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